Chemotherapy Biotherapy Certification ONS Practice Testq

What impact does the use of G-CSF have on patients undergoing chemotherapy?

1. It prolongs chemotherapy cycles

2. It reduces the incidence of febrile neutropenia

3. It increases the need for blood transfusions

4. It has no impact on chemotherapy outcomes

The correct answer is: It reduces the incidence of febrile neutropenia

The use of Granulocyte-Colony Stimulating Factor (G-CSF) is critical in the management of patients undergoing chemotherapy due to its primary function in stimulating the bone marrow to produce more neutrophils, a type of white blood cell crucial for fighting infection. Chemotherapy often leads to myelosuppression, where the bone marrow's ability to produce blood cells is significantly decreased. As a result, patients are at a higher risk for febrile neutropenia, a potentially serious condition characterized by fever and a significantly low neutrophil count. By administering G-CSF, the recovery of neutrophil counts is expedited, thus lowering the risk of febrile neutropenia and its complications. This intervention can significantly impact the patient’s ability to endure subsequent chemotherapy cycles without delays or adjustments in dosing due to low white blood cell counts. Consequently, this enhances the likelihood that patients can maintain the planned chemotherapy schedule, which is vital for the efficacy of cancer treatment. In summary, G-CSF serves to directly reduce the incidence of febrile neutropenia in patients receiving chemotherapy, improving their overall treatment experience and safety.